GlassScriptPhysician profile
Nathan H Au
NPI 1629051750
$2,363.33
in general payments reported to CMS, 2019-2025
13 companies · $353 in 2025
The $353 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $134 · 2021: $562 · 2022: $168 · 2023: $476 · 2024: $314 · 2025: $353.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $612.72 | 2020-2025 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $320.15 | 2021-2025 | Total30, Precision 1, Dailies Total1 |
| Astellas Pharma US INC | $259.49 | 2024-2025 | Izervay |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $231.67 | 2019 | |
| Ivantis, INC | $228.41 | 2021 | |
| Glaukos Corporation | $154.92 | 2025 | Idosetr |
| Johnson & Johnson Vision Care, INC. | $140.82 | 2023 | Acuvue |
| Bausch & Lomb Americas INC. | $135.19 | 2023-2025 | Vyzulta, Miebo, Xiidra |
| Sight Sciences, INC. | $124.99 | 2019 | |
| Apellis Pharmaceuticals, INC. | $93.30 | 2024 | Syfovre |
| Abb Con-Cise Optical Group LLC | $25.03 | 2024 | Spectacle Lenses, Contact Lens |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Au listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.